
-
AnaptyBio Inc NASDAQ:ANAB Imsidolimab, previously known as ANB019, is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which AnaptysBio plans to initially develop as a potential first-in-class therapy for patients suffering from generalized pustular psoriasis, or GPP, EGFR-mediated skin toxicity, ichthyosis, hidradenitis suppurativa and acne.
Location: 10421 Pacific Center Ct Ste 200, California, 92121-4339, US | Website: www.anaptysbio.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
502.6M
Cash
430.1M
Avg Qtr Burn
-25.75M
Short % of Float
37.72%
Insider Ownership
4.44%
Institutional Own.
-
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
JEMPERLI (Dostarlimb-gxly) Details Solid tumor/s, Cancer, Endometrial cancer | Approved Quarterly sales | |
Jemperli (dostarlimab) + Zejula (niraparib) Details Ovarian cancer, Cancer | Phase 3 Data readout | |
Dostarlimab+ belrestotug Details Non-small cell lung carcinoma, Cancer | Phase 3 Data readout | |
Dostarlimab Details Non-small cell lung carcinoma, Cancer | Phase 3 Data readout | |
Imsidolimab (ANB019) (anti-IL-36R) Details Hidradenitis suppurativa, Generalized pustular psoriasis, EGFRi-mediated skin toxicity, Ichthyosis, Palmoplantar pustulosis, Acne | Phase 3 Update | |
Rosnilimab (ANB030) (PD-1 agonist) Details Rheumatoid arthritis, Autoimmune disease | Phase 2b Data readout | |
Rosnilimab (ANB030) (PD-1 agonist) Details Ulcerative colitis | Phase 2 Data readout | |
ANB033 (anti-CD122 antagonist antibody) Details Inflammatory disease | Phase 1b Update | |
ANB101 (BDCA2 modulator) Details Ulcerative colitis | Phase 1 Initiation | |
Etokimab (ANB020) Anti-IL-33 Details Chronic Rhinosinusitis with Nasal Polyps | Failed Discontinued | |
ANB032 (BTLA agonist) Details Atopic dermatitis | Failed Discontinued | |
Rosnilimab (ANB030) (PD-1 agonist) Details Alopecia areata, Vitiligo, Skin disease/disorder | Failed Discontinued |